Psoriasis Treatment Market driven by High-Priced Biologics to Reach US$ 9.7 Billion by 2021

Psoriasis is a chronic immune-mediated skin disorder that affects about 2–3% of the population worldwide. Topical treatments such as form of lotions, foams, creams, ointments, gels, and shampoos containing steroids, tar preparations, and calcium- modulating drugs are very useful because they are relatively safe, fairly effective, and can be applied directly to the affected skin. Most oral medications act by targeting portions of the immune system. Phototherapy or light therapy, involves exposing the skin to ultraviolet light on a regular basis and under medical supervision. A range of agents are available for the symptomatic treatment of psoriasis. Treatments for more advanced psoriasis include narrow-band ultraviolet B (UVB) light, psoralen with ultraviolet A (UVA) light retinoids (isotretinoin [Accutane, Claravis], acitretin [Soriatane]), methotrexate (particularly for arthritis), cyclosporine (Neoral, Sandimmune), infliximab (Remicade), etanercept (Enbrel), adalimumab (Humira), apremilast (Otezla), and secukinumab (Cosentyx). Currently, calcineurin inhibitors such as tacrolimus (Prograf) and pimecrolimus (Elidel) are approved only for the treatment of atopic dermatitis. Vitamin D analogues such as Calcipotriene (Dovonex) slow down the growth of skin cells.

Biologic drugs are usually prescribed for moderate to severe psoriasis and psoriatic arthritis that has not responded to other treatments. The first biologic agent for psoriasis, the tumour necrosis factor (TNF) antagonist etanercept (Enbrel; Amgen), was approved in 2004. With a number of branded specialty biologics set to lose their exclusivity status in many of the larger markets, growth is likely to be affected by biosimilar erosion. Biosimilar infliximab (Remsima; Celltrion, or Inflectra; Hospira) is already available in several markets, including the European Union and Japan, and is under review by the FDA. Biosimilars of etanercept and biosimilar adalimumab are also likely to launch during the forecast period.

Browse Psoriasis Treatment Market by Drug Class (Interleukin Blockers, TNF Inhibitors, Vitamin D Analogues or Combinations, Others), Therapy Type (Systemic Therapeutic Drugs, Topical Therapeutic Drugs, Combinations, Others), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/

The global psoriasis treatment market segmentation is based on drug class (interleukin blockers, TNF inhibitors, vitamin d analogues or combinations, others), therapy type (systemic therapeutic drugs, topical therapeutic drugs, combinations, others), distribution channel (hospital pharmacy, online sales, retail pharmacy, others).

The global psoriasis treatment market report provides market size (US$ million 2014-2021), market share, trends and forecasts growth trends (CAGR%, 2017-2021). The global psoriasis treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global psoriasis treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global psoriasis treatment market and profiled in this report include AbbVie, Inc., Almirall, Amgen, Inc., AstraZeneca, Biogen, Eli Lilly & Company, Forward Pharma, GlaxoSmithKline, Johnson & Johnson (Janssen Biotech), LEO Pharma A/S, Maruho, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Promius Pharma, and Therapeutics, Inc.

1. Drug Class
1.1. Interleukin Blockers
1.2. TNF Inhibitors
1.3. Vitamin D Analogues or Combinations
1.4. Others

2. Therapy Type
2.1. Systemic Therapeutic Drugs
2.2. Topical Therapeutic Drugs
2.3. Combinations
2.4. Others

3. Distribution Channel
3.1. Hospital Pharmacy
3.2. Online Sales
3.3. Retail Pharmacy
3.4. Others

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. AbbVie, Inc.
5.2. Almirall
5.3. Amgen, Inc.
5.4. AstraZeneca
5.5. Biogen
5.6. Eli Lilly & Company
5.7. Forward Pharma
5.8. GlaxoSmithKline
5.9. Johnson & Johnson (Janssen Biotech)
5.10. LEO Pharma A/S
5.11. Maruho
5.12. Merck & Co., Inc.
5.13. Novartis AG
5.14. Pfizer, Inc.
5.15. Promius Pharma
5.16. Therapeutics, Inc.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/psoriasis-treatment-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.